Endocrine Disrupting BPA Found in more than 67% of all Food Cans!

by | Apr 3, 2016


March 30, 2016 – A brand new report found 67% of nearly 200 food cans from dozens of brands and retailers tested positive for the toxic chemical Bisphenol A (BPA), a hormone disrupting chemical linked to breast and prostate cancer, infertility, type-2 diabetes and ADHD.
Kroger and Campbell’s Soup are food industry leaders who have the power and a moral responsibility to get toxic chemicals like BPA out of food packaging. Kroger is the largest supermarket chain in the United States, and Campbell’s is one of the most iconic food brands, sold in 120 countries around the world.

Both companies have pledged to reduce their use of BPA in food cans, yet a new report found that most of their cans sampled still tested positive for this harmful chemical. According to the report, Buyer Beware: Toxic BPA and regrettable substitutes found in the linings of canned food, every single one of the Campbell’s Soup cans analyzed tested positive for BPA, and 62% of Kroger’s did as well! Meanwhile, some other leading brands have already eliminated BPA from their can linings.

Studies have shown this hormonally active chemical can migrate out of cans, get into the food our families eat, and make its way into our bodies, where it may be harmful to our health. BPA clearly has no place in the canned foods we buy for our families!

What is Bis-Phenol A (BPA)

BPA is a synthetic estrogen that is recognized as an endocrine-disrupting chemical because of its effects on hormone systems. Studies raised concerns that exposure to even low doses of the chemical may increase the risk of breast and prostate cancer, infertility, type-2 diabetes, obesity and attention deficit hyperactivity disorder (ADHD). The doses in question, measurable in parts per billion and even parts per trillion, are comparable to the amounts an average person can be exposed to through canned food packaging.

Data from the U.S. Centers for Disease Control and Prevention indicate that 93 percent of Americans5 tested have detectable levels of BPA in their urine6,7 suggesting that people are consistently exposed and re-exposed to BPA through the chemical’s presence in foods and from other sources. BPA has been detected in breast milk, amniotic fluid and umbilical cord blood, suggesting that babies are exposed to BPA as newborns and even before they are born, during critical windows of development and vulnerability.8

References: Buyer Beware (National Cancer Fund) 

A green chalkboard with the message 'I LOVE YOU' written in white chalk.Please Help Ban BPA

Your health depends on it. Please tell Campbell’s Soups, Kroger Foods and others to “eliminate BPA from all food containers. You don’t want to be exposed to synthetic estrogens that put you at increased risk of getting breast cancer!”


Sign the Petition

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

6 + 13 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });